Research & Reviews: Journal of Oncology and Hematology Cover

Research & Reviews: Journal of Oncology and Hematology

ISSN: 2319-3387

Editors Overview

rrjooh maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

Open Access
Special Issue
Topic

Methods of Cell Therapy

Abstract Submission Deadline : November 30, 2024

Manuscript Submission Deadline : December 25, 2024

Special Issue Description

Cell treatments hold up the possibility of treating and reversing the progression of illnesses that can’t be adequately treated by current medications. Cell therapies are a diverse group that spans a variety of cell types and therapeutic indications. The use of cell therapy has been around since the 19th century and is still growing due to financial and research reasons. Cell therapy encompasses stem cell- and non-stem cell-based, monocellular, and multicellular treatments with various immunophenotypic profiles, isolation methods, modes of action, and regulatory levels. Human cells are transplanted during cellular therapy (CT) to replace or restore harmed tissue or cells. Numerous different types of cells may be used as part of a therapy or treatment for several diseases and disorders with the help of new technologies, inventive products, and infinite imagination. Hematopoietic (blood-forming) stem cells (HSC), skeletal muscle stem cells, mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells are a few of the cells that could be used. Cell treatments may be used to treat conditions like cancer, autoimmune diseases, urinary issues, infectious diseases, and spinal cord injuries, as well as to restore damaged cartilage in joints and cure patients with neurological abnormalities. When treating cancer that has advanced in stage, traditional cytotoxic methods for neoplastic illnesses are only somewhat effective. Patients respond to treatment in different ways, and the high rate of relapse with poor prognosis continues to be a difficult problem. The introduction of cell therapy changed the face of cancer treatment during the past few decades. In this special issue, we invite articles based on many distinct types of cell therapy, including stem cell-based and non-stem cell-based cell therapies, and various “multicellular” therapies applied in clinical settings. It also covers the advantages of cell therapies reported in 3 therapeutic areas—regenerative medicine, immunological illnesses, and cancer—as well as the specifics of FDA policies governing their use. Because the regulatory process and manufacturing solutions are frequently similar within a technology area due to the nature of the methods used, the issue focuses on the description and classification of cell therapies based on their underlying technologies rather than the more popular classification by cell type. It also publishes articles describing how innovative cell therapies are meeting the clinical, regulatory, manufacturing, and reimbursement criteria; analyzes their progress toward clinical translation; identifies some of the remaining hurdles, and offers ideas on how the area can develop in the future.

Keywords

Cell therapy, Regenerative medicine, Non-stem cell-based cell therapy, Stem cell-based cell therapy, Hematopoietic stem cells (HSC)

Manuscript Submission information

Manuscripts should be submitted online via the manuscript Engine. Once you register on APID, click here to go to the submission form. Manuscripts can be submitted until the deadline.
All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a Double-blind peer-review process. A guide for authors and other relevant information for the submission of manuscripts is available on the Instructions for Authors page.

Participating journals:


2319-3387

Journal Name

Research & Reviews: Journal of Oncology and Hematology

Abbrivation


rrjooh

ISSN


2319-3387

Since

2012

APC

950  $